A Study of Teropavimab and Zinlirvimab in Combination With Capsid Inhibitor Lenacapavir in Virologically Suppressed Adults With HIV-1 Infection
Phase 2
Active, not recruiting
NCT05729568
| Condition | HIV-1 Infection |
|---|
| Phase | Phase 2 |
|---|
| Sponsor | Gilead Sciences |
|---|
| Status | Active, not recruiting |
|---|
| Enrollment | 83 participants |
|---|
| Interventions | Teropavimab, Zinlirvimab, Lenacapavir Tablet, Lenacapavir Injection, Antiretroviral Therapy |
|---|
| Start date | May 15, 2023 |
|---|
| Completion date | Jul 2, 2024 |
|---|
| Results posted | Jul 15, 2025 |
|---|
Summary
The goal of this study is to test the effectiveness, safety, and tolerability of the combination of broadly neutralizing antibodies (bNAbs) (teropavimab (TAB; GS-5423) and zinlirvimab (ZAB; GS-2872)) with lenacapavir (LEN) in virologically suppressed adults with HIV-1 infection. The purpose of this study is to evaluate the efficacy of switching to a regimen of LEN, TAB and ZAB, versus continuing on baseline oral antiretroviral therapy (ART) as determined by the proportion of participants with human immunodeficiency virus-1 (HIV-1) ribonucleic acid (RNA) ≥ 50 copies/mL at Week 26.
Percentage of Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Ribonucleic Acid (RNA) ≥ 50 Copies/mL at Week 26 as Determined by the United States Food and Drug Administration (US FDA)-Defined Snapshot Algorithm
Week 26 · percentage of participants
| Randomized Phase Treatment Group 1: LEN + TAB+ ZAB | 1.9 percentage of participants |
|---|
| Randomized Phase Treatment Group 3: SBR | 0.0 percentage of participants |
|---|
| p-value | 1.0000 |
|---|
| Difference in Percentages | 1.9 (95% CI -11.2–10.6) |
|---|
Open in BENITIONS
View on ClinicalTrials.gov
All trials
This page summarises publicly available data from ClinicalTrials.gov. It is not medical advice and not investment advice. Always consult a qualified healthcare professional.